Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Protelos | 3M Pharmaceuticals (Now iNOVA ) | Accord Healthcare(K) Ltd | 2g | 28 | Powder | KES 5199.12 |
| Strontium Ranelate More info | |
|---|---|
| Mode Of Action | Strontium Ranelate increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture; and reduces bone resorption by decreasing osteoclast differentiation and resorbing activity. |
| Drug Indication | Postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures. Treatment of osteoporosis in men at increased risk of fracture. |
| Precautions | Not recommended in patients with a creatinine clearance below 30ml/min due to lack of data. Use with caution in patients at increased risk of venous thromboembolism (VTE) including patients with a history of VTE. Use inductively coupled plasma atomic emission spectrometry or an atomic absorption spectrometry method to assess blood and urinary calcium concentrations as strontium interferes with colorimetric methods. In case of hypersensitivity induced cutaneous manifestations therapy should be stopped immediately and not re-started. Use with caution in patients with phenylketonuria, as it contains phenylalanine. |
| Contra-Indications | Hypersensitivity to the active substance or to any of the excipients; patients with current VTE or a history of VTE, as well as patients who are temporarily or permanently immobilised. |
| Side Effects | Nausea, diarrhoea, loose stools, headache, dermatitis, eczema, memory loss, seizures.Skin reactions: Life-threatening cutaneous reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported with the use of Strontium Ranelate.Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of tre |
| Dosage | 1 sachet diluted in half a glass of water taken once daily. |
| Special Information | Method of administration: For oral use. The granules in the sachets must be taken as a suspension in a glass containing a minimum of 30 ml (approximately one third of a standard glass) of water. Although in-use studies have demonstrated that strontium ranelate is stable in suspension for 24 hours after preparation, the suspension should be drunk immediately after being prepared. |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Anti-thyroid medicines |